Dar Faisal Saud, Bhatti Abu Bakar Hafeez, Dogar Abdul-Wahab, Zia Haseeb, Amin Sadaf, Rana Atif, Nazer Rashid, Khan Nasir Ayub, Khan Etizaz-ud-din, Rajput Muhammad Zameer, Salih Muhammad, Shah Najmul Hassan
Departments of Hepato-Pancreato-Biliary and Liver Transplant Surgery.
Radiology.
Liver Transpl. 2015 Jul;21(7):982-90. doi: 10.1002/lt.24151.
Living donor liver transplantation (LDLT) is the only treatment option for patients with end-stage liver disease (ESLD) where cadaveric donors are not available. In developing countries, the inception of LDLT programs remains a challenge. The first successful liver transplantation program in Pakistan started transplantation in 2012. The objective of this study was to report outcomes of 100 LDLT recipients in a developing country and to highlight the challenges encountered by a new LDLT program in a resource-limited setting. We retrospectively reviewed recipients who underwent LDLT between April 2012 and August 2014. Demographics, etiology, graft characteristics, and operative variables were assessed. Outcome was assessed on the basis of morbidity and mortality. All complications of ≥ 3 on the Clavien-Dindo grading system were included as morbidity. Estimated 1-year survival was calculated using Kaplan-Meier curves, and a Log-rank test was used to determine the significance. Outcomes between the first 50 LDLTs (group 1) and latter 50 LDLTs (group 2) were also compared. Median age was 46.5 (0.5-72) years, whereas the median MELD score was 15.5 (7-37). The male to female ratio was 4:1. ESLD secondary to hepatitis C virus was the most common indication (73% patients). There were 52 (52%) significant (≥ grade 3) complications. The most common morbidities were bile leaks in 9 (9%) and biliary strictures in 14 (14%) patients. Overall mortality in patients who underwent LDLT for ESLD was 10.6%. Estimated 1-year survival was 87%. Patients who underwent transplantation in the latter period had a significantly lower overall complication rate (36% versus 68%; P = 0.01). Comparable outcomes can be achieved in a new LDLT program in a developing country. Outcomes improve as experience increases.
活体肝移植(LDLT)是终末期肝病(ESLD)患者在无法获得尸体供体时的唯一治疗选择。在发展中国家,启动LDLT项目仍然是一项挑战。巴基斯坦首个成功的肝移植项目于2012年开始进行移植手术。本研究的目的是报告一个发展中国家100例LDLT受者的治疗结果,并强调在资源有限的环境中一个新的LDLT项目所面临的挑战。我们回顾性分析了2012年4月至2014年8月期间接受LDLT的受者。评估了人口统计学、病因、移植物特征和手术变量。根据发病率和死亡率评估结果。Clavien-Dindo分级系统中≥3级的所有并发症均被纳入发病率统计。使用Kaplan-Meier曲线计算估计的1年生存率,并使用对数秩检验确定其显著性。还比较了前50例LDLT(第1组)和后50例LDLT(第2组)的治疗结果。中位年龄为46.5(0.5 - 72)岁,而中位终末期肝病模型(MELD)评分是15.5(7 - 37)。男女比例为4:1。丙型肝炎病毒继发的ESLD是最常见的适应证(73%的患者)。有52例(52%)严重(≥3级)并发症。最常见的发病情况是9例(9%)出现胆漏,14例(14%)出现胆管狭窄。因ESLD接受LDLT的患者总体死亡率为10.6%。估计1年生存率为87%。后期接受移植的患者总体并发症发生率显著较低(36%对68%;P = 0.01)。在发展中国家的一个新的LDLT项目中可以取得可比的治疗结果。随着经验的增加,治疗结果会有所改善。